Project Grant R34AI184112
- This federal Project Grant award of $644,770 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research grant program (CFDA 93.855), will support research to determine the impact of immunosuppression on the risk of post-transplant lymphoproliferative disorder (PTLD) and Epstein-Barr virus (EBV) infection in kidney transplant recipients receiving EBV-seropositive donor organs. The project aims to identify modifiable risk factors,...
- This Project Grant award of $441,522 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research CFDA program supports research to reduce the need for systemic immunosuppression in kidney transplant patients. The objective is to test the efficacy and safety of pre-transplant modification of the kidney graft with a small molecule integrin inhibitor, delivered via ex vivo perfusion, to decrease immune cell recruitment and improve...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research CFDA program (93.855), will provide $205,901 to fund two clinical studies conducted by the Fred Hutchinson Cancer Center in Seattle, Washington. The first study will be a randomized, controlled, multicenter trial of intravenous immunoglobulin replacement therapy (IGRT) in 150 adult chimeric antigen receptor T-cell (CART) therapy recipients,...
- This federal Project Grant award of $286,791, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop pediatric-specific blood transcriptional modules (pBTMs) that capture the broad range of heterogeneous physiological states in children across diverse geographical settings. The project will construct these modules using transcriptome data from over 13,000 samples across 76 studies...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $153,512 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Leland Stanford Junior University. The grant will fund research to characterize the renal immune microenvironment in antibody-mediated rejection (ABMR) of kidney transplants in order to develop improved diagnostics and predict treatment response. The research will utilize advanced imaging mass cytometry to profile...
- The federal Project Grant award of $3,106,301 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate the mechanisms underlying induction and maintenance of immunosuppression and the impact on T cell function after kidney transplantation. The project aims to analyze epigenetic, transcriptional, and immune phenotype changes associated with the use of antithymocyte globulin (ATG)...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research at New York University (NYU) to develop personalized immunosuppression regimens for kidney transplant recipients. The $847,371 award, with a project period from September 15, 2025 to July 31, 2030, will leverage a large nationwide electronic health record database to...
- This federal Project Grant award, with a total funding of $642,056, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research to characterize plasma cell infiltrates in cardiac allograft vasculopathy (CAV), a leading cause of morbidity and mortality after heart transplantation. The key objectives are to: 1) characterize the clonal composition and transcriptome profile...
- This $612,975 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to develop an approach combining T cell costimulation blockade and inhibition of monocyte allorecognition via CD47 to achieve long-term acceptance of solid organ transplants without the need for ongoing immunosuppression. The research aims...
- The National Institute of Allergy and Infectious Diseases (NIAID), through its Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $1,135,986 Project Grant to Northwestern University. The grant, effective January 1, 2025, aims to identify cellular and molecular targets for developing tissue/cell-specific strategies to prevent cytomegalovirus (CMV) reactivation and improve outcomes in kidney transplant recipients. The research will investigate the role of...
This $235,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support the development of infrastructure and documents to conduct a clinical trial evaluating the use of intravenous immunoglobulin (IVIG) to treat BK polyomavirus infections in pediatric kidney transplant recipients. The award will fund a planning grant to establish a prospective cohort of 120 pediatric kidney transplant recipients across 7 major U.S. sites. The goal is to mimic an ongoing adult clinical trial that is assessing the therapeutic efficacy of IVIG for sustained BK polyomavirus infections, which can lead to premature kidney transplant loss in the absence of effective preventative or treatment strategies. The project aims to address the lack of clinical trials focused on pediatric transplant recipients, who are at high risk of severe primary BK polyomavirus infections due to limited prior exposure and immunity.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $235.5k | 8/28/25 |